Aug 23 (Reuters) - Teva Pharmaceutical Industries (NYSE:TEVA) Ltd TEVA.TA
* Teva Canada Innovation says in addition to newly approved dose, daily COPAXONE 20 mg/ml will continue to be available
* Times-A-Week COPAXONE 40mg/ml by Health Canada Source text for Eikon: ID:nCNWYlpXGa Further company coverage: TEVA.TA